Executive Summary

The Federal Council opened the public consultation procedure on the second cost containment package in the pharmaceutical sector on 18 February 2026. The package of measures decided by Parliament in March 2025 aims to slow the rise in health care costs in mandatory health insurance (OKP) and relieve premium payers. The planned changes are intended to promote access to innovative therapies, improve pharmaceutical supply, and simultaneously achieve savings.

Persons

  • Federal Council (collectively)

Topics

  • Health policy
  • Cost containment
  • Pharmaceutical regulation
  • Health insurance

Clarus Lead

The Federal Council launches public consultation on pharmaceutical sector ordinance amendments that are part of the second cost containment program. These measures address rising mandatory health insurance expenditures and are intended to reduce premium pressure. The consultation concerns amendments to the Health Insurance Ordinance (KVV) and the Health Care Benefits Ordinance (KLV), which represent a balancing act between promoting innovation and controlling costs.

Detailed Summary

The two-stage cost containment program of Swiss health policy focuses on slowing expenditure increases in the insurance system. The second package, already adopted by Parliament, contains several legislative changes whose concrete implementation is now entering the consultation phase. This phase enables stakeholders from medicine, pharmacy, insurance, and civil society to submit comments on the planned ordinance amendments.

The pharmaceutical sector changes pursue a dual objective: on the one hand, innovative therapies should remain accessible and even be promoted; on the other hand, cost-effectiveness and supply security must be ensured. The measures thus address the central challenge of Swiss health policy – how to reconcile quality and innovation with cost responsibility.

Key Messages

  • The Federal Council opens consultation on pharmaceutical sector ordinance amendments as part of Cost Containment Package 2
  • The objective is to slow OKP expenditure increases to relieve premium payers
  • The measures should promote access to innovation and optimize pharmaceutical supply while achieving savings
  • Affected ordinances: KVV and KLV
  • Legal basis: Parliament adopted the package in March 2025

Critical Questions

  1. Evidence Quality: On what cost projections and savings scenarios is the assumption based that the planned ordinance changes will lead to measurable cost containment? What empirical data from comparable countries were used?

  2. Conflicts of Interest: How is it ensured that the consultation takes all relevant stakeholders (patient organizations, generic manufacturers, innovation companies) equally into account and does not allow pharmaceutical lobby interests to dominate?

  3. Causality and Alternatives: Are pharmaceutical costs actually the primary cost driver in OKP, or does the package address only one aspect? Were alternative measures (e.g., prevention, efficiency gains in hospital care) evaluated as equally important?

  4. Implementation Risks: How is it prevented that cost containment measures lead to supply gaps for rare diseases or vulnerable population groups? What protective clauses are provided?

  5. Transparency of Consultation: How long is the consultation period, and will the submitted comments be made public?

  6. Innovation Promotion vs. Cost Control: How concretely will the two objectives (innovation promotion and cost savings) be operationalized if they potentially conflict?

Sources

Primary Source: Press Release: Implementation of Cost Containment Package 2 – Opening of Public Consultation on Pharmaceuticals – https://www.news.admin.ch/de/newnsb/lCw7tC_x3NSVit2XLLYny

Verification Status: ✓ 19 February 2026

This text was created with the support of an AI model. Editorial responsibility: clarus.news | Fact-checking: 19 February 2026